Navigation Links
Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
Date:5/15/2012

SOUTH EASTON, Mass., May 15, 2012 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2012 financial results and to provide a business update.  Anyone interested may listen to the teleconference either by telephone or through a live web-cast.  The teleconference and web-cast information is provided below:

Date:  Wednesday, May 16, 2012
Time: 4:15 p.m. Eastern Daylight Time (EDT)

To attend this teleconference via web-cast, please visit the Company's website:
www.pressurebiosciences.com

To attend this teleconference via telephone:
Dial-in: (888) 383-9147

For those unable to participate in the live teleconference, a replay will be available approximately one hour after the call ends through June 16, 2012, and will be accessible through the Company's website. 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT").  PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market.  PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions.  PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Investor Contacts:
Pressure BioSciences, Inc.
Richard T. Schumacher, President & CEO
Joseph Damasio, Jr., VP of Finance & Administration
(
T) 508-230-1828


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Failure to Take Medicine Linked to Unnecessary Hospital Visits, Especially for Medicare Patients Taking High Blood Pressure or High Cholesterol Medications
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Europe Patient Monitoring Market Outlook to 2017 - Fetal Monitors, Multiparameter Patient Monitoring, Neonatal Monitors, Non-Invasive Blood Pressure Monitors, Remote Patient Monitoring and Others
4. North America Patient Monitoring Market Outlook to 2017 - Fetal Monitors, Multiparameter Patient Monitoring, Neonatal Monitors, Non-Invasive Blood Pressure Monitors, Remote Patient Monitoring and Others
5. Femasys Receives FDA 510(k) Clearance for First Low Pressure HSG Device
6. ICU Medical Launches Neutron™ Needlefree Catheter Patency Device With Constant Neutral Pressure Backed by a $100,000 Guarantee to Reduce Catheter Occlusions
7. Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets
8. iHealth Labs Blood Pressure Self-Monitoring System Gets Nationwide Distribution
9. FDA: Treatment With Angiotensin Receptor Blockers for High Blood Pressure Does Not Increase Risk of Cancer
10. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
11. Wellsense Unveils First-Ever Bedside Patient Pressure Mapping System Designed to Assist Caregivers in Effectively Repositioning Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop ... knew it was something that contractors should have at their disposal on a ... says Butch, CertainTeed’s Director of Contractor Programs. , As a result, Metloop ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of “lean manufacturing” in ... well. However, laboratories have different challenges compared to manufacturing environments. , In order ... lab, METTLER TOLEDO has developed the Lean Lab Checklist . This checklist will ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... on patients with cancer, has added Cancer and Careers to its ... more timely content on continuing successful careers while fighting cancer. , As partners, ...
Breaking Medicine News(10 mins):